董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas H. Jensen | 男 | Chief Executive Officer and Director | 47 | 未披露 | 未持股 | 2026-09-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey S. Ervin | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2026-09-10 |
| Thomas H. Jensen | 男 | Chief Executive Officer and Director | 47 | 未披露 | 未持股 | 2026-09-10 |
董事简历
中英对照 | 中文 | 英文- Thomas H. Jensen
-
Thomas H.Jensen自2020年6月以来一直担任我们的前身Allarity Therapeutics A/S的信息技术高级副总裁，并继续担任我们的信息技术高级副总裁。Jensen先生曾于2004年至2020年6月担任我们前任的首席技术官。Jensen先生于2004年共同创立Allarity Therapeutics A/S。Jensen先生还在丹麦建立并领导我们的实验室。除了培育我们的全球实验室，Jensen先生在建立我们的投资者关系运营，获得运营融资以及促进Allarity Therapeutics的业务增长方面发挥了重要作用。Jensen先生的荣誉之一是他的分子生物学指南的发明，结合了高质量可重复的RNA提取和下游加工技术。这允许对癌症患者的活检进行高分辨率分析。Jensen先生的发明是DRP®；药物反应预测平台的重要基础。Jensen先生拥有丹麦技术大学的生物学学士学位，并在哥本哈根大学进行了生物学的进一步研究。
Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company's since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of Allarity Therapeutics, Inc.'s predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of Allarity Therapeutics, Inc.'s predecessor from 2004 to June 2020. Mr. Jensen co founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads Allarity Therapeutics, Inc.'s laboratories in Denmark. Alongside nurturing Allarity Therapeutics, Inc.'s global laboratories, Mr. Jensen is instrumental in building Allarity Therapeutics, Inc.'s investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen's accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients' biopsies. Mr. Jensen's inventions are an important foundation of the DRP Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen. - Thomas H.Jensen自2020年6月以来一直担任我们的前身Allarity Therapeutics A/S的信息技术高级副总裁，并继续担任我们的信息技术高级副总裁。Jensen先生曾于2004年至2020年6月担任我们前任的首席技术官。Jensen先生于2004年共同创立Allarity Therapeutics A/S。Jensen先生还在丹麦建立并领导我们的实验室。除了培育我们的全球实验室，Jensen先生在建立我们的投资者关系运营，获得运营融资以及促进Allarity Therapeutics的业务增长方面发挥了重要作用。Jensen先生的荣誉之一是他的分子生物学指南的发明，结合了高质量可重复的RNA提取和下游加工技术。这允许对癌症患者的活检进行高分辨率分析。Jensen先生的发明是DRP®；药物反应预测平台的重要基础。Jensen先生拥有丹麦技术大学的生物学学士学位，并在哥本哈根大学进行了生物学的进一步研究。
- Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company's since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of Allarity Therapeutics, Inc.'s predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of Allarity Therapeutics, Inc.'s predecessor from 2004 to June 2020. Mr. Jensen co founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads Allarity Therapeutics, Inc.'s laboratories in Denmark. Alongside nurturing Allarity Therapeutics, Inc.'s global laboratories, Mr. Jensen is instrumental in building Allarity Therapeutics, Inc.'s investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen's accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients' biopsies. Mr. Jensen's inventions are an important foundation of the DRP Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen.
高管简历
中英对照 | 中文 | 英文- Jeffrey S. Ervin
Jeffrey S. Ervin， Ddc Enterprise Limited联席首席财务官。他于2015年3月共同创立了IMAC Holdings， Inc.（纳斯达克股票代码：BACK），并担任其首席执行官兼董事会主席，直到2024年5月。2011年10月至2015年3月，Ervin先生担任Medicare.com母公司Medx Publishing的高级财务官，负责建立行政职能，以满足CMS教育部门的快速增长。在此期间至2015年3月，Medicare.com获得INC. 500的认可，他在收购Medicaid.com（出售给United Healthcare Group）的过程中发挥了重要作用。2006年至2011年9月，Ervin先生担任纳什维尔浸信会医院系统的高级财务分析师和财务副总裁，负责采购和管理直接投资以满足养老金义务。他在范德比尔特大学获得工商管理硕士学位，在迈阿密大学获得金融学士学位。
Jeffrey S. Ervin has served on Board since February 2024. Mr. Ervin has served as Chief Financial Officer of Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical stage, precision medicine company actively advancing a pipeline of in licensed oncology therapeutics, since July 2025. From June 2024 to January 2025, he served in a fractional capacity as co chief financial officer of DDC Enterprise, Ltd (NYSE: DDC). Prior to DDC, he served as chairman and chief executive officer of IMAC Holdings, Inc. between February 2015 and May 2024. Mr. Ervin was co founder of IMAC Holdings, Inc. and led an initial public offering in February 2019 (Nasdaq: BACK). Mr. Ervin earned his Master of Business Administration from Vanderbilt University and his Bachelor of Science in Finance from Miami University.- Jeffrey S. Ervin， Ddc Enterprise Limited联席首席财务官。他于2015年3月共同创立了IMAC Holdings， Inc.（纳斯达克股票代码：BACK），并担任其首席执行官兼董事会主席，直到2024年5月。2011年10月至2015年3月，Ervin先生担任Medicare.com母公司Medx Publishing的高级财务官，负责建立行政职能，以满足CMS教育部门的快速增长。在此期间至2015年3月，Medicare.com获得INC. 500的认可，他在收购Medicaid.com（出售给United Healthcare Group）的过程中发挥了重要作用。2006年至2011年9月，Ervin先生担任纳什维尔浸信会医院系统的高级财务分析师和财务副总裁，负责采购和管理直接投资以满足养老金义务。他在范德比尔特大学获得工商管理硕士学位，在迈阿密大学获得金融学士学位。
- Jeffrey S. Ervin has served on Board since February 2024. Mr. Ervin has served as Chief Financial Officer of Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical stage, precision medicine company actively advancing a pipeline of in licensed oncology therapeutics, since July 2025. From June 2024 to January 2025, he served in a fractional capacity as co chief financial officer of DDC Enterprise, Ltd (NYSE: DDC). Prior to DDC, he served as chairman and chief executive officer of IMAC Holdings, Inc. between February 2015 and May 2024. Mr. Ervin was co founder of IMAC Holdings, Inc. and led an initial public offering in February 2019 (Nasdaq: BACK). Mr. Ervin earned his Master of Business Administration from Vanderbilt University and his Bachelor of Science in Finance from Miami University.
- Thomas H. Jensen
Thomas H.Jensen自2020年6月以来一直担任我们的前身Allarity Therapeutics A/S的信息技术高级副总裁，并继续担任我们的信息技术高级副总裁。Jensen先生曾于2004年至2020年6月担任我们前任的首席技术官。Jensen先生于2004年共同创立Allarity Therapeutics A/S。Jensen先生还在丹麦建立并领导我们的实验室。除了培育我们的全球实验室，Jensen先生在建立我们的投资者关系运营，获得运营融资以及促进Allarity Therapeutics的业务增长方面发挥了重要作用。Jensen先生的荣誉之一是他的分子生物学指南的发明，结合了高质量可重复的RNA提取和下游加工技术。这允许对癌症患者的活检进行高分辨率分析。Jensen先生的发明是DRP®；药物反应预测平台的重要基础。Jensen先生拥有丹麦技术大学的生物学学士学位，并在哥本哈根大学进行了生物学的进一步研究。
Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company's since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of Allarity Therapeutics, Inc.'s predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of Allarity Therapeutics, Inc.'s predecessor from 2004 to June 2020. Mr. Jensen co founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads Allarity Therapeutics, Inc.'s laboratories in Denmark. Alongside nurturing Allarity Therapeutics, Inc.'s global laboratories, Mr. Jensen is instrumental in building Allarity Therapeutics, Inc.'s investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen's accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients' biopsies. Mr. Jensen's inventions are an important foundation of the DRP Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen.- Thomas H.Jensen自2020年6月以来一直担任我们的前身Allarity Therapeutics A/S的信息技术高级副总裁，并继续担任我们的信息技术高级副总裁。Jensen先生曾于2004年至2020年6月担任我们前任的首席技术官。Jensen先生于2004年共同创立Allarity Therapeutics A/S。Jensen先生还在丹麦建立并领导我们的实验室。除了培育我们的全球实验室，Jensen先生在建立我们的投资者关系运营，获得运营融资以及促进Allarity Therapeutics的业务增长方面发挥了重要作用。Jensen先生的荣誉之一是他的分子生物学指南的发明，结合了高质量可重复的RNA提取和下游加工技术。这允许对癌症患者的活检进行高分辨率分析。Jensen先生的发明是DRP®；药物反应预测平台的重要基础。Jensen先生拥有丹麦技术大学的生物学学士学位，并在哥本哈根大学进行了生物学的进一步研究。
- Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company's since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of Allarity Therapeutics, Inc.'s predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of Allarity Therapeutics, Inc.'s predecessor from 2004 to June 2020. Mr. Jensen co founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads Allarity Therapeutics, Inc.'s laboratories in Denmark. Alongside nurturing Allarity Therapeutics, Inc.'s global laboratories, Mr. Jensen is instrumental in building Allarity Therapeutics, Inc.'s investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen's accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients' biopsies. Mr. Jensen's inventions are an important foundation of the DRP Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen.